p16/INK4a IHC (cervical dysplasia discrimination)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-P16-IHC-CERVICAL-DYSPLASIA |
|---|---|
| Type | Biomarker |
| Aliases | CDKN2A IHCp16 IHC for cervical CIN/HSILp16 block-positive stainingp16-INK4a immunohistochemistryp16/INK4a ІГХ (диференціація цервікальної дисплазії) |
| Status | reviewed 2026-05-18 |
| Diseases | None declared |
| Sources | SRC-ESMO-CERVICAL-2024 SRC-NCCN-CERVICAL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC on FFPE cervical biopsy; CINtec p16 antibody (clone E6H4 — LAST/CAP-validated) Unitscategorical: block-positive (diffuse strong nuclear+cytoplasmic in basal/parabasal third) | focal/negative |
| Related biomarkers | None declared |
Notes
STUB. LAST/CAP-recommended adjunct IHC to distinguish CIN2 (HSIL biology — block-positive p16) from CIN1 (LSIL, mimicking metaplasia — focal/ negative). Block-positive p16 = surrogate for HR-HPV-driven transforming infection; upgrades CIN2 morphologic equivocal cases into HSIL, triggering excisional treatment (LEEP/cold-knife conization) rather than observation. Not a treatment-selection variant biomarker — IHC surrogate only.
Used By
No reverse references found in the YAML corpus.